Cantor Fitzgerald Reiterates Aytu Biosciences (AYTU) at Overweight, $11 PT, Sees it as Positive Development Potentially Extending ADHD Franchise Revenue Runway
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $11.00 price target on Aytu Biosciences (NASDAQ: AYTU), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
